Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

Executive Summary

The competitive bidding process for Medivation shows just how much big pharma is willing to pay for commercial-stage oncology assets. Now that Pfizer has won the biotech, it will have to prove Xtandi is worth the price.

Advertisement

Related Content

Pfizer Poised To PROSPER From Xtandi In Expanded Indication
Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation
Pfizer's Oncology Strategy Centers On Three Anchors To Steady The Ship
Myovant On Path To Women’s Health Leadership, CEO Says
Big Pharma Is Back In The M&A Driver’s Seat For 2017
With Medivation, Pfizer Sees A Chance For More Combinations
Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole
Mylan Turns To Meda In Sweden For Open Door Into Consumer Market
Medivation/Astellas’ Xtandi A Tough Rival For J&J’s Zytiga

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC097164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel